Because of their high incidence in undifferentiated thyroid cancer, the presence of P53 mutations may be predictive of a highly aggressive thyroid cancer, but on its own, sensitivity is too low to be used as a reliable clinical biomarker. The gene discussed is TP53; the disease is thyroid cancer.